Freenome's $254M Boost for Early Cancer Detection
February 20, 2024, 7:30 pm
Location: United States, California, South San Francisco
Employees: 201-500
Founded date: 2014
Total raised: $1.05B
Freenome, a biotech company in San Francisco, just secured a massive $254M in funding to advance their blood-based cancer detection tests. The investment, led by Roche and backed by a slew of other big names, will propel Freenome's mission to catch cancer early and save lives.
Freenome's cutting-edge multiomics platform, powered by computational biology and machine learning, is at the forefront of developing screening tools for detecting cancer in its most treatable stages. Their focus on deadly and actionable cancers like colorectal and lung is driving the development of single-cancer and multi-cancer tests that could revolutionize early detection.
With ongoing clinical studies like PREEMPT CRC and PROACT LUNG, Freenome is on the fast track to bringing these tests to market. But they're not stopping there. The Vallania Study, a multi-cancer research program with over 6,200 participants, is paving the way for even more breakthroughs in cancer detection.
CEO Mike Nolan expressed gratitude for the investors' support, highlighting their shared commitment to making early cancer detection more accessible and actionable for everyone. With this funding, Freenome is poised to unleash the full potential of their platform and deliver life-saving tests to those who need them most.
Freenome's cutting-edge multiomics platform, powered by computational biology and machine learning, is at the forefront of developing screening tools for detecting cancer in its most treatable stages. Their focus on deadly and actionable cancers like colorectal and lung is driving the development of single-cancer and multi-cancer tests that could revolutionize early detection.
With ongoing clinical studies like PREEMPT CRC and PROACT LUNG, Freenome is on the fast track to bringing these tests to market. But they're not stopping there. The Vallania Study, a multi-cancer research program with over 6,200 participants, is paving the way for even more breakthroughs in cancer detection.
CEO Mike Nolan expressed gratitude for the investors' support, highlighting their shared commitment to making early cancer detection more accessible and actionable for everyone. With this funding, Freenome is poised to unleash the full potential of their platform and deliver life-saving tests to those who need them most.